Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Systemic Lupus Erythematosus
2017-001489-53Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Ustekinumab with Placebo (2 arms). Primary endpoint: Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at Week 52. Started Mar 2018; status: terminated.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2017-001489-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001489-53.